Neuroblastoma (NB) is a rare but aggressive pediatric cancer, the third most-common in children and the most frequent in babies. Researchers from the U.S. National Cancer Institute and collaborators have reported findings from their study investigating the use of [67Cu]Cu-LLP2A as radiopharmaceutical therapy before CAR T-cell treatment in preclinical models of NB.

Brightpath Biotherapeutics Co. Ltd. has submitted an IND application to the FDA to initiate a phase I trial of BP-2202 in the U.S. (NCT07667868).

Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.